

# Is it too late to invest in healthcare and tech?


FOR QUALIFIED CLIENTS, WHOLESAL, PROFESSIONAL CLIENTS, PROFESSIONAL INVESTORS, QUALIFIED, SOPHISTICATED AND INSTITUTIONAL INVESTORS USE ONLY – NOT FOR PUBLIC DISTRIBUTION (PLEASE READ IMPORTANT DISCLOSURES)

**BlackRock**

Despite a challenging economic backdrop the last few quarters, equities have performed strongly and companies have been putting up solid numbers. As the activity restart continues, however, we're seeing a new set of obstacles including percolating inflation and supply chain disruptions. Likewise, "COVID-winner" sectors like tech and healthcare have been more challenged in recent months, and investment flows into them have tapered off. Have we reached the end of the road for the strong performance of these sectors?

Our BlackRock experts believe there is still room to grow, and our outlook on equities remains constructive relative to other asset classes – but less so than in previous quarters.

## Assets in review – still room to run for tech and healthcare?



Past performance is not a reliable indicator of current or future results. Indexes are unmanaged and do not account for fees. It is not possible to invest directly in an index. Sources: BlackRock Investment Institute, with data from Refinitiv Datastream as of June 10, 2021. Notes: The two ends of the bars show the lowest and highest returns at any point this year to date, and the dots represent current year-to-date returns. Emerging market (EM), high yield and global corporate investment grade (IG) returns are denominated in U.S. dollars, and the rest in local currencies. Indexes or prices used are, in descending order: spot Brent crude, MSCI Europe Index, MSCI USA Index, MSCI Emerging Markets Index, Bank of America Merrill Lynch Global High Yield Index, ICE U.S. Dollar Index (DXY), spot gold, J.P. Morgan EMBI index, Bank of America Merrill Lynch Global Broad Corporate Index, Refinitiv Datastream Italy 10-year benchmark government bond index, Refinitiv Datastream Germany 10-year benchmark government bond index and Refinitiv Datastream U.S. 10-year benchmark government bond index.

### Healthcare


We remain constructive on healthcare as a structural growth sector and from a near-term valuation perspective, supported by long-term drivers of aging populations fueling an increasing demand for healthcare, as well as increased innovation and efficiency in the bio-tech industry. Last year was an unprecedented one for healthcare, and while many companies experienced short-term setbacks we don't forecast any slow-down in demand going forward.

### Technology

Technology was the best performing sector last year and has demonstrated sustained outperformance. External factors like rising interest rates may be putting a temporary pause on the sector momentum, but technology is at the structural core of every industry – and something the global economy can't function without. As in healthcare, we don't see a scenario in which demand for technology decreases over the medium- to long-term.

## ETP sector flows Jan 2020 – June 2021

Tech cooling off? Outflows from tech ETPs in May & June; Investors add to healthcare ETPs in May



Source: BlackRock and Markit data, 11 June 2021

## Contributors



**Tony Kim**  
Portfolio Manager, Global Technology Funds, Fundamental Equity



**Kate Moore**  
Global Allocation Team, Head of Thematic Strategy



**Erin Xie**  
Portfolio Manager, Health Sciences, Active Equity Group

*In conversation with*



**Isabelle Mateos y Lago**, Global Head, Official Institutions Group

# Is it too late to invest in healthcare and tech?

**Isabelle Mateos y Lago (IML):** Kate, what have you learned from Q1 earnings season? And what's your outlook through the end of the year?

**Kate Moore (KM):** It was an exceptional quarter and very unique because of the comparisons to Q1 2020 from when most of the world was locking down or locked down. With close to 50% year-over-year growth, earnings were outstanding globally and particularly in the U.S.

**Three observations round out the story for Q1 earnings reporting:**

- **Ex ante positioning matters:** while we saw some incredible numbers, not everyone was a winner – in fact, most winners were not rewarded by the market with higher stock prices. There was a bit of a gap between some published forecasts and what buy-side investors were expecting, and equity markets had moved in advance of earnings releases. For the most part, investors are already long equities, so there wasn't much room to add even for some of these companies that are posting great numbers.
- **Looming inflation:** we've seen aggressive cost control that resulted in impressive improvements and pre-tax margins for many companies, not just in Q1 but in H2 2020 as well. Now we're discussing percolating inflation, the sustainability of inflation, labor shortages, supply chain disruptions, and the challenges of the activity restart, whether in services or in the manufacturing sector. This leaves huge uncertainty for margins over coming quarters. We'll be watching very closely in H2 this year what margins look like, given these broad-based issues around supply chain and labor.
- **Policy matters:** whether its fiscal or monetary policy, policy has a significant impact on perceptions of earnings as well as the outlook for equities. Our research has indicated most companies weren't talking about policy changes coming down the pike or factoring them into their own estimates, however – so there is a bit of uncertainty around what the impact of policy will ultimately be.


With these considerations in mind, I expect we'll see even more upward revisions to earnings, even in a period where the market is range-bound. Across the whole spectrum of assets, from rates and currencies to credit and commodities, we still think equities have the most powerful and durable upside.

**IML:** Erin, if we look at Q1 earnings and performance over the last 12 months, healthcare has been somewhat lagging the broader market which seems counterintuitive in the middle of a global pandemic. Looking at things with a longer-term perspective, where are we right now in terms of the attractiveness of the healthcare sector?

**Erin Xie (EX):** We remain very constructive on healthcare, given our belief it's a structural growth sector supported by long-term drivers and developments. This makes the underlying companies very attractive from an active investment perspective.

**Innovations:** We see a new wave of medicines being developed, from a decade of genomics research contributing to a better understanding of diseases to bio-pharma advancements in the drug development space. In bio-tech, we also see strong innovations in invasive surgeries and the incorporation of digital technology in medical equipment and diagnostic tools, enabling patients to have better communication with providers and allowing them to monitor their health in a more efficient way. We also see new business models being developed to address healthcare delivery and efficiency, incorporating technology.

## Price index and forward earnings continue upward trend, P/E ratios remain well above average




Past performance is not a reliable indicator of current or future results. Indices are unmanaged and do not account for fees. It is not possible to invest directly in an index.


Source: Refinitiv Datastream, MSCI and BlackRock Investment Institute, June 15m 2021. Notes: The lines on the top graph are the components of the P/E ratios on the lower graph since 2003. The P/E ratios are calculated using I/B/E/S earnings statements for the next 12 months.

## Long-term structural tailwinds: Innovation

### Rise of Robotic Assisted Surgery



### Reduced Genome Sequencing Costs



Left hand chart: Jama Network, January 2020. Right hand chart: Source: NIH National Human Genome Research Institute, May 2020.



# Is it too late to invest in healthcare and tech?

**Demographic shifts:** We see demographic shifts across the globe in all major countries and populations. If we think about the U.S., 1 in 5 people will be over the age of 65 – and Europe and Asia are aging too. This population shift will provide strong demand growth for healthcare, as an elderly population consumes more healthcare than a younger one. In Emerging Markets (EM), there's a significant gap in healthcare spending compared to Developed Markets (DM). There's significant demand growth from EM economies, however, and we think healthcare spending will outpace economic growth in these countries over the coming years and decades.

## Long-term structural tailwinds: Demand growth

### Proportion of population 65+

### Healthcare spending as a percentage of GDP



Source: (1) World Bank data and estimates, current as at February 28, 2021. (2) Deloitte 2019 Outlook for Healthcare (3) The World Bank, Current as at February 28, 2021, based on 2018 expenditures. For illustrative purposes only. There is no guarantee that forecasts made will come to pass.

Regarding relative performance over the past year, the health crisis was an unprecedented time with many healthcare companies experiencing near-term setbacks, such as cancellations of elective surgeries. There's also the inflation concern – but when we think about healthcare, we tend to focus on long-term demand, which we don't think would be impacted by an inflationary environment. Valuations are very attractive relative to the market, as healthcare multiples are below the long-term average: this underscores why we think healthcare is attractive from a near-term valuation perspective as well as a long-term structural growth perspective.

**IML:** Tony, the tech sector has been the darling of investors for some time now and even more so since the pandemic started and has done incredibly well. Is it too late or is it still a great time for loading up on the tech sector?


**Tony Kim (TK):** I've been asked the question about whether it's too late for tech for the past ten years; seemingly the answer every year has been no, it's not too late. After a stellar 2020, however, we seem to be taking a pause – though we're not expecting this pause to be long-lasting.

The technology industry has been the best performing not just last year, but over the last 5, 10, 15 years; it has been a systematic structural industry that's gone from 20% of the S&P to nearly 40% over the last 20 years. The centerpiece of all of this is that structurally and fundamentally, this is an industry that is a horizontal enabling tool made up of two components: code running on the chip, and software running on silicon. With a given business model you build a product, app, or service, and through applying this horizontal technology you promote and create new businesses attached to every industry. As a result, the tech industry's horizontal enablement has become like a predatory animal, attacking industries one by one and allowing it to double in market cap. It now affects and influences every sector on the planet – no company can function without software, and what we saw with COVID-19 was the proliferation of these tools into every single facet of the economy.

To me, the best measure of whether it's too late to invest in technology is the pace of change. If the pace at which the world and industries are changing is slowing down we will see less innovation. Then we don't invest in tech. But if you think the world is continually going to change at a rapid pace, you need these horizontal enabling tools. The rate of change, particularly over the past 10 years, has accelerated to a pace we've never seen before. In this kind of environment, regardless of GDP or macro outlook or inflationary environment, the technology sector will do well over a long-term time horizon.

## Growing importance of tech is reflected in equity markets

### Tech's market share in broad equity indices continues to grow



Source: Morningstar, FactSet September 30, 2020. For illustrative purposes only.

# Is it too late to invest in healthcare and tech?

**IML:** The sector is very diverse, and it is challenging to think about valuation holistically. Having said that, we're almost certainly heading into a phase of rising interest rates. We don't know exactly when it will be, but we are confident this is the direction of travel. Does this impact the way you're thinking about the sector?

**TK:** On a tactical basis, yes. We've adjusted to this new reality in terms of portfolio composition for the higher-rate environment. The market is not paying attention to interest rates for long-term cash flows of cyclical companies, but eventually all companies have long-term free cash flow valuations. We consider this through a lens in which value is captured in the longer duration and we adjust to higher discount rates, which is the current tactical reality. A rising rate and inflation environment will hurt growth companies, but ultimately it will hurt everyone because everyone is going to be based on a long-term cash flow. Ultimately, you're starting to see these valuation gaps: if the gap between value and growth tech was huge last year, now they've reversed year-to-date. At some point, I don't know when, we're going to determine this 150% growth in the cyclical rebound is not 'real' growth. That's a once-in-a-cycle kind of growth.

**IML:** Lets pivot now to geography – this is not strictly a U.S. conversation. Kate, you tend to like U.S. markets better than others – is this the case now as well despite richer valuations, or do you see better opportunities in other parts of the market?

**KM:** When I think about positioning from a global equity perspective, it's more about choosing the best and most exciting industries. I favor a barbell approach, with a significant portion of equity allocations in the U.S., and then a fair amount from China and other parts of emerging Asia where we see durable and dynamic growth. In Europe, I believe we need to be selective in choosing high-quality companies that have flexibility, are competitive relative to their peer group, and are forward-thinking, as opposed to an index approach.

Past performance is not a reliable indicator of current or future results. Indices are unmanaged and do not account for fees. It is not possible to invest directly in an index. Source: Refinitiv Datastream, chart by BlackRock Investment Institute, June 15 2021. Notes: The lines show the performance of each index over a 5-year period. The index performance is in local currency.



**IML:** Erin, Tony, where do you see the highest-growth markets in healthcare and tech?

**EX:** The highest-growth part of the market will be companies that are the most innovative. For the time being, we've seen the U.S. as the leader in healthcare innovation in medical technology and bio-pharma – but China is catching up. From a demand growth perspective, the U.S. and Europe are already mature markets, so we'll likely see stronger growth in EM. I'd expect a large market like China will continue to see strong growth.

**TK:** In technology some new things have come to light, which I believe ultimately favor the U.S.:

- U.S.–China tensions are centered on technology. China has realized their vulnerabilities where they were not owning or controlling certain technologies necessary to be an economic superpower. This creates a new 'cold war' of trying to control foundational technologies around semiconductors and software.
- Chinese tech companies are being subjected to tremendous anti-trust scrutiny, which are having a significant impact compared to the what US tech giants face in this respect.
- The GDP growth rate differential between the U.S. and China has significantly declined, diminishing the allure of China. In fact this is the case with a lot of EM, which begs the question of what exactly is the appeal?
- A lot of the cutting-edge foundation for new technology is still centered in the U.S. While China is catching up in certain areas, it still lags in others – and the rest of the world is far behind them.

**IML:** What are the key risks on the horizon that would change your outlooks?

**KM:** I think the hot debate right now is on the durability of inflation. We've acknowledged we're going to get higher inflation and rising prices across a variety of industries, but I think a big risk would be if this doesn't turn out to be transitory, and we need to resort to recalculating risk and opportunity sets for U.S. and global companies.

**EX:** Regulation is always a risk for healthcare, though given the government makeup we're not really expecting drastic legislative changes right now. Another risk would be a new COVID variant that's unresponsive to current vaccines, forcing R&D to start from square one.

**TK:** The risks are out of our control, like inflation duration – which has the capacity to change the regime of investors' mentality and what they're interested in. My other concern is geopolitical risk around Taiwan, the epicenter of the global technology supply chain. I think regulation is a risk in China, but less so in the U.S.

## The decoupling of globalized supply chains continues to intensify, as the US and China compete for technological dominance



There is no guarantee that any forecasts made will come to pass. Source: BofA Research Investment Committee, OECD.





## Important Information

BIMAL, its officers, employees and agents believe that the information in this material and the sources on which it is based (which may be sourced from third parties) are correct as at the date of publication. While every care has been taken in the preparation of this material, no warranty of accuracy or reliability is given and no responsibility for the information is accepted by BIMAL, its officers, employees or agents. Except where contrary to law, BIMAL excludes all liability for this information.

**In the U.S.**, this material is intended for Institutional Investors only – not for public distribution.

**In Canada**, this material is intended for permitted clients only, is for educational purposes only, does not constitute investment advice and should not be construed as a solicitation or offering of units of any fund or other security in any jurisdiction.

**In Latin America, for institutional investors and financial intermediaries only (not for public distribution).** This material is for educational purposes only and does not constitute investment advice or an offer or solicitation to sell or a solicitation of an offer to buy any shares of any fund or security and it is your responsibility to inform yourself of, and to observe, all applicable laws and regulations of your relevant jurisdiction. If any funds are mentioned or inferred in this material, such funds may not be registered with the securities regulators of Argentina, Brazil, Chile, Colombia, Mexico, Panama, Peru, Uruguay or any other securities regulator in any Latin American country and thus, may not be publicly offered in any such countries. The securities regulators of any country within Latin America have not confirmed the accuracy of any information contained herein. No information discussed herein can be provided to the general public in Latin America. The contents of this material are strictly confidential and must not be passed to any third party.

**In Argentina**, only for use with Qualified Investors under the definition as set by the Comisión Nacional de Valores (CNV). In Brazil, this private offer does not constitute a public offer, and is not registered with the Brazilian Securities and Exchange Commission, for use only with professional investors as such term is defined by the Comissão de Valores Mobiliários. In Colombia, the sale of each fund discussed herein, if any, is addressed to less than one hundred specifically identified investors, and such fund may not be promoted or marketed in Colombia or to Colombian residents unless such promotion and marketing is made in compliance with Decree 2555 of 2010 and other applicable rules and regulations related to the promotion of foreign financial and/or securities related products or services in Colombia. In Chile, the sale of each fund not registered with the CMF is subject to General Rule No. 336 issued by the SVS (now the CMF). The subject matter of this sale may include securities not registered with the CMF; therefore, such securities are not subject to the supervision of the CMF. Since the securities are not registered in Chile, there is no obligation of the issuer to make publicly available information about the securities in Chile. The securities shall not be subject to public offering in Chile unless registered with the relevant registry of the CMF. In Peru, this private offer does not constitute a public offer, and is not registered with the Securities Market Public Registry of the Peruvian Securities Market Commission, for use only with institutional investors as such term is defined by the Superintendencia de Banca, Seguros y AFP. In Uruguay, the Securities are not and will not be registered with the Central Bank of Uruguay. The Securities are not and will not be offered publicly in or from Uruguay and are not and will not be traded on any Uruguayan stock exchange. This offer has not been and will not be announced to the public and offering materials will not be made available to the general public except in circumstances which do not constitute a public offering of securities in Uruguay, in compliance with the requirements of the Uruguayan Securities Market Law (Law N° 18.627 and Decree 322/011).

**In Colombia**, the offer of each Fund is addressed to less than one hundred specifically identified investors, and such Fund may not be promoted or marketed in Colombia or to Colombian residents unless such promotion and marketing is made in compliance with Decree 2555 of 2010 and other applicable rules and regulations related to the promotion of foreign financial and/or securities related products or services in Colombia.

**In Peru**, this material is for the sole use of Institutional Investors, as such term is defined by the Superintendencia de Banca, Seguros y AFP

## Important Information

**In Chile**, the offer of each security not registered with the Comisión para el Mercado Financiero (“CMF”) is subject to General Rule No. 336 issued by the SVS (now the CMF). The subject matter of this offer may include securities not registered with the CMF; therefore, such securities are not subject to the supervision of the CMF. Since the securities are not registered in Chile, there is no obligation of the issuer to make publicly available information about the securities in Chile. The securities shall not be subject to public offering in Chile unless registered with the relevant registry of the CMF.

**For investors in Central America**, these securities have not been registered before the Securities Superintendence of the Republic of Panama, nor did the offer, sale or their trading procedures. The registration exemption has made according to numeral 3 of Article 129 of the Consolidated Text containing of the Decree-Law No. 1 of July 8, 1999 (institutional investors). Consequently, the tax treatment set forth in Articles 334 to 336 of the Unified Text containing Decree-Law No. 1 of July 8, 1999, does not apply to them. These securities are not under the supervision of the Securities Superintendence of the Republic of Panama. The information contained herein does not describe any product that is supervised or regulated by the National Banking and Insurance Commission (CNBS) in Honduras. Therefore any investment described herein is done at the investor’s own risk. This is an individual and private offer which is made in Costa Rica upon reliance on an exemption from registration before the General Superintendence of Securities (“SUGEVAL”), pursuant to articles 7 and 8 of the Regulations on the Public Offering of Securities (“Reglamento sobre Oferta Pública de Valores”). This information is confidential, and is not to be reproduced or distributed to third parties as this is NOT a public offering of securities in Costa Rica. The product being offered is not intended for the Costa Rican public or market and neither is registered or will be registered before the SUGEVAL, nor can be traded in the secondary market. If any recipient of this documentation receives this document in El Salvador, such recipient acknowledges that the same has been delivered upon his request and instructions, and on a private placement basis.

**IN MEXICO, FOR INSTITUTIONAL AND QUALIFIED INVESTORS USE ONLY. INVESTING INVOLVES RISK, INCLUDING POSSIBLE LOSS OF PRINCIPAL. THIS MATERIAL IS PROVIDED FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR SOLICITATION TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SHARES OF ANY FUND OR SECURITY.** This information does not consider the investment objectives, risk tolerance or the financial circumstances of any specific investor. This information does not replace the obligation of financial advisor to apply his/her best judgment in making investment decisions or investment recommendations. It is your responsibility to inform yourself of, and to observe, all applicable laws and regulations of Mexico. If any funds, securities or investment strategies are mentioned or inferred in this material, such funds, securities or strategies have not been registered with the Mexican National Banking and Securities Commission (Comisión Nacional Bancaria y de Valores, the “CNBV”) and thus, may not be publicly offered in Mexico. The CNBV has not confirmed the accuracy of any information contained herein. The provision of investment management and investment advisory services (“Investment Services”) is a regulated activity in Mexico, subject to strict rules, and performed under the supervision of the CNBV. These materials are shared for information purposes only, do not constitute investment advice, and are being shared in the understanding that the addressee is an Institutional or Qualified investor as defined under Mexican Securities (Ley del Mercado de Valores). Each potential investor shall make its own investment decision based on their own analysis of the available information. Please note that by receiving these materials, it shall be construed as a representation by the receiver that it is an Institutional or Qualified investor as defined under Mexican law. BlackRock México Operadora, S.A. de C.V., Sociedad Operadora de Fondos de Inversión (“BlackRock México Operadora”) is a Mexican subsidiary of BlackRock, Inc., authorized by the CNBV as a Mutual Fund Manager (Operadora de Fondos), and as such, authorized to manage Mexican mutual funds, ETFs and provide Investment Advisory Services. For more information on the Investment Services offered by BlackRock Mexico, please review our Investment Services Guide available in [www.blackrock.com/mx](http://www.blackrock.com/mx). This material represents an assessment at a specific time and its information should not be relied upon by the you as research or investment advice regarding the funds, any security or investment strategy in particular. Reliance upon information in this material is at your sole discretion. BlackRock México is not authorized to receive deposits, carry out intermediation activities, or act as a broker dealer, or bank in Mexico. For more information on BlackRock México, please visit: [www.blackrock.com/mx](http://www.blackrock.com/mx). BlackRock receives revenue in the form of advisory fees for our advisory services and management fees for our mutual funds, exchange traded funds and collective investment trusts. Any modification, change, distribution or inadequate use of information of this document is not responsibility of BlackRock or any of its affiliates. Pursuant to the Mexican Data Privacy Law (Ley Federal de Protección de Datos Personales en Posesión de Particulares), to register your personal data you must confirm that you have read and understood the Privacy Notice of BlackRock México Operadora.

## Important Information

For the full disclosure, please visit [www.blackRock.com/mx](http://www.blackRock.com/mx) and accept that your personal information will be managed according with the terms and conditions set forth therein. BlackRock® is a registered trademark of BlackRock, Inc. All other trademarks are the property of their respective owners.

**For investors in the Caribbean**, any funds mentioned or inferred in this material have not been registered under the provisions of the Investment Funds Act of 2003 of the Bahamas, nor have they been registered with the securities regulators of Bermuda, Dominica, the Cayman Islands, the British Virgin Islands, Grenada, Trinidad & Tobago or any jurisdiction in the Organisation of Eastern Caribbean States, and thus, may not be publicly offered in any such jurisdiction. The shares of any fund mentioned herein may only be marketed in Bermuda by or on behalf of the fund or fund manager only in compliance with the provision of the Investment Business Act 2003 of Bermuda and the Companies Act of 1981. Engaging in marketing, offering or selling any fund from within the Cayman Islands to persons or entities in the Cayman Islands may be deemed carrying on business in the Cayman Islands. As a non-Cayman Islands person, BlackRock may not carry on or engage in any trade or business unless it properly registers and obtains a license for such activities in accordance with the applicable Cayman Islands law.

**In EMEA: This material is for distribution to Professional Clients (as defined by the Financial Conduct Authority or MiFID Rules) only and should not be relied upon by any other persons.**

Issued by BlackRock Investment Management (UK) Limited, authorised and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL. Tel: + 44 (0)20 7743 3000. Registered in England and Wales No. 02020394. For your protection telephone calls are usually recorded. Please refer to the Financial Conduct Authority website for a list of authorised activities conducted by BlackRock.

Until 31 December 2020, issued by BlackRock Investment Management (UK) Limited, authorised and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL. Tel: + 44 (0)20 7743 3000. Registered in England and Wales No. 02020394. For your protection telephone calls are usually recorded. Please refer to the Financial Conduct Authority website for a list of authorised activities conducted by BlackRock.

From 1 January 2021, in the event the United Kingdom and the European Union do not enter into an arrangement which permits United Kingdom firms to offer and provide financial services into the European Economic Area, the issuer of this material is:

(i) BlackRock Investment Management (UK) Limited for all outside of the European Economic Area; and

(ii) BlackRock (Netherlands) B.V. for in the European Economic Area,

BlackRock (Netherlands) B.V. is authorised and regulated by the Netherlands Authority for the Financial Markets. Registered office Amstelplein 1, 1096 HA, Amsterdam, Tel: 020 – 549 5200, Tel: 31-20-549-5200. Trade Register No. 17068311 For your protection telephone calls are usually recorded.

**For qualified investors in Switzerland: This document is marketing material.**

Until 31 December 2021, this document shall be exclusively made available to, and directed at, qualified investors as defined in the Swiss Collective Investment Schemes Act of 23 June 2006 ("CISA"), as amended.

From 1 January 2022, this document shall be exclusively made available to, and directed at, qualified investors as defined in Article 10 (3) of the CISA of 23 June 2006, as amended, at the exclusion of qualified investors with an opting-out pursuant to Art. 5 (1) of the Swiss Federal Act on Financial Services ("FinSA").

For information on art. 8 / 9 Financial Services Act (FinSA) and on your client segmentation under art. 4 FinSA, please see the following website: [www.blackrock.com/finsa](http://www.blackrock.com/finsa)

## Important Information

**In Saudi Arabia** The information contained in this document is intended strictly for sophisticated institutions.

The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of BlackRock.

The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public.

The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser.

**In the UAE** The information contained in this document is intended strictly for non-natural Qualified Investors as defined in the UAE Securities and Commodities Authority’s Board Decision No. 3/R.M of 2017 concerning Promoting and Introducing Regulations.

The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of BlackRock.

The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public.

The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser.

**In Kuwait** The information contained in this document is intended strictly for sophisticated institutions that are ‘Professional Clients’ as defined under the Kuwait Capital Markets Law and its Executive Bylaws.

The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of BlackRock.

The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public.

The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser.

# Important Information

**Qatar** The information contained in this document is intended strictly for sophisticated institutions.

The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of BlackRock

The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public.

The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser.

**Dubai (DIFC)** The information contained in this document is intended strictly for Professional Clients as defined under the Dubai Financial Services Authority (“DFSA”) Conduct of Business (COB) Rules.

The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of BlackRock. The information contained in this document is for information purposes only. It is not intended for and should not be distributed to, or relied upon by, members of the public. The information contained in this document, may contain statements that are not purely historical in nature but are “forward-looking statements”. These include, amongst other things, projections, forecasts or estimates of income. These forward-looking statements are based upon certain assumptions, some of which are described in other relevant documents or materials. If you do not understand the contents of this document, you should consult an authorised financial adviser.

**In South Africa**, please be advised that BlackRock Investment Management (UK) Limited is an authorised Financial Services provider with the South African Financial Services Conduct Authority, FSP No. 43288.

**In Israel:** BlackRock Investment Management (UK) Limited is not licenced under Israel's Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 5755-1995 (the “Advice Law”), nor does it carry insurance thereunder.

**In Azerbaijan, Botswana, Jordan, Kazakhstan, Mauritius, Namibia, and Uganda:** the information contained in this document is intended strictly for Central Banks and Sovereign Investors.

The information contained in this document, does not constitute and should not be construed as an offer of, invitation or proposal to make an offer for, recommendation to apply for or an opinion or guidance on a financial product, service and/or strategy. Whilst great care has been taken to ensure that the information contained in this document is accurate, no responsibility can be accepted for any errors, mistakes or omissions or for any action taken in reliance thereon. You may only reproduce, circulate and use this document (or any part of it) with the consent of BlackRock.

## Important Information

The information provided here is neither tax nor legal advice. Investors should speak to their tax professional for specific information regarding their tax situation. Investment involves risk including possible loss of principal. International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation, and the possibility of substantial volatility due to adverse political, economic or other developments. These risks are often heightened for investments in emerging/developing markets or smaller capital markets.

This document is for your use only and must not be circulated to anyone else without BlackRock's consent or provided to the general public under any circumstances.

Any research in this document has been procured and may have been acted on by BlackRock for its own purpose. The results of such research are being made available only incidentally. The views expressed do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of any company in the BlackRock Group or any part thereof and no assurances are made as to their accuracy.

This document is for information purposes only and does not constitute an offer or invitation to anyone to invest in any BlackRock funds and has not been prepared in connection with any such offer.

© 2021 BlackRock, Inc. All Rights reserved. BLACKROCK, BLACKROCK SOLUTIONS, iSHARES, BUILD ON BLACKROCK and SO WHAT DO I DO WITH MY MONEY are trademarks of BlackRock, Inc. or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners.